Vianna Rodrigo, Kubal Chandrashekhar, Mangus Richard, Fridell Jonathan, Tector Joseph
Department of Surgery, Division of Transplantation, Indiana University School of Medicine/Clarian Transplant Institute, Indianapolis, Indiana, USA.
Clin Transpl. 2009:219-28.
Intestinal transplantation has shown exceptional growth over the past 20 years with extraordinary progress. As with other solid organ transplants, intestinal transplantation has now transitioned from being experimental to being the standard of care for patients with intestinal failure. The currently reported 1-year graft and patient survival rate is 80%, which approaches that for other solid abdominal organs. Unfortunately, most of the gains in survival are seen in the first postoperative year, with long-term survival remaining basically unchanged since the early 1990s. Immunosuppressive regimens continue to evolve, with induction therapy being the major change in the past 10 years. No randomized trials compare intestinal transplantation to long-term PN to establish guidelines for timely referral for this treatment option, so late referral remains a crippling problem in the field of intestinal transplantation. Patients referred late often develop severe liver dysfunction and fibrosis, resulting in a great number of patients in need of simultaneous liver transplantation at the time of listing for intestinal transplantation.
在过去20年里,肠道移植取得了非凡进展,实现了显著增长。与其他实体器官移植一样,肠道移植如今已从实验阶段转变为肠道衰竭患者的标准治疗方式。目前报告的1年移植物和患者存活率为80%,接近其他腹部实体器官的存活率。不幸的是,大部分存活获益见于术后第一年,自20世纪90年代初以来长期存活率基本未变。免疫抑制方案持续演变,诱导治疗是过去10年中的主要变化。尚无随机试验将肠道移植与长期肠外营养进行比较以确立该治疗选择的适时转诊指南,因此转诊过晚仍是肠道移植领域的一个严重问题。转诊过晚的患者常出现严重肝功能障碍和纤维化,导致大量患者在登记接受肠道移植时需要同时进行肝移植。